Federal award (DEFINITIVE CONTRACT, fiscal year 2022)
Recipient: ENTASIS THERAPEUTICS INC.
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2020-07-01 to 2022-12-31
Current total value of award: $5863913
Description: TO IDENTIFY AND DEVELOP A NON-BETA-LACTAM PBP INHIBITOR (NBP) WITH BROAD SPECTRUM OF ACTIVITY AGAINST MDR GRAM-NEGATIVE ESKAPE PATHOGENS.